ESR1 and cancer: In a study examining responses of ER+ primary cancers to neoadjuvant chemotherapy, macrophage content did not vary among luminal A, B and basal subtypes, but an M1 signature was associated with a more favorable response to treatment, and an M2 signature was increased post-chemotherapy, suggesting that targeting this population may provide additional benefit [52].